Literature DB >> 11497342

Drug use during early pregnancy. The impact of maternal illness, outcome of prior pregnancies and socio-demographic factors.

H Nordeng1, A Eskild, B I Nesheim, I Aursnes, G Jacobsen.   

Abstract

OBJECTIVE: Socio-demographic factors have been associated with drug use in pregnancy. However, information on maternal illness has rarely been included in previous studies. The aim of this study was therefore to estimate the impact of maternal illness and prior pregnancy outcome on the use of analgesics/antipyretics, anti-infectives and antihistamines in early pregnancy controlling for socio-demographic factors.
METHODS: One thousand nine-hundred and forty-five parous pregnant women from Norway and Sweden were included in an interview study. Information on drug use, obstetric history, maternal illness and socio-demographic factors was collected by specially trained midwives at gestational week 17 and form the basis for the present analyses.
RESULTS: After control for socio-demographic factors, reported illness was associated with the use of analgesics/antipyretics, anti-infectives and antihistamines during early pregnancy. The use of analgesic/antipyretic and anti-infective drugs differed between study sites. Sociodemographic factors such as age, parity, marital status, education, occupation and smoking habits did not influence drug use in the multivariate analysis.
CONCLUSION: Maternal illness during pregnancy was associated with drug use in early pregnancy. When studying factors related to drug use during pregnancy, it is important to include information on maternal illness. Socio-demographic factors may be confounders and lead to erroneous conclusions about the factors related to drug use.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11497342     DOI: 10.1007/s002280100304

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Prescription drugs during pregnancy and lactation--a Finnish register-based study.

Authors:  Heli Malm; Jaana Martikainen; Timo Klaukka; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2003-04-17       Impact factor: 2.953

2.  Guidelines for iron supplementation in pregnancy: compliance among 431 parous Scandinavian women.

Authors:  H Nordeng; A Eskild; B-I Nesheim; I Aursnes; G Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  2003-05-07       Impact factor: 2.953

3.  Drug exposure during the periconceptional period: a study of 1793 women.

Authors:  Elisabeth Autret-Leca; Jean Deligne; Joffray Leve; Agnès Caille; Hawaré Cissoko; Annie Pierre Jonville-Bera
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

4.  Predictors of the use of medications before and during pregnancy.

Authors:  Marina Odalovic; Sandra Vezmar Kovacevic; Hedvig Nordeng; Katarina Ilic; Ana Sabo; Ljiljana Tasic
Journal:  Int J Clin Pharm       Date:  2013-02-07

5.  Effects of personality on use of medications, alcohol, and cigarettes during pregnancy.

Authors:  Eivind Ystrom; Margarete E Vollrath; Hedvig Nordeng
Journal:  Eur J Clin Pharmacol       Date:  2011-12-22       Impact factor: 2.953

6.  Associations between socio-economic factors and the use of prescription medication during pregnancy: a population-based study among 19,874 Danish women.

Authors:  Charlotte Olesen; Nana Thrane; Tine Brink Henriksen; Vera Ehrenstein; Jørn Olsen
Journal:  Eur J Clin Pharmacol       Date:  2006-05-04       Impact factor: 2.953

7.  Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women.

Authors:  Siri Amundsen; Torunn G Øvrebø; Netta Marie S Amble; Anne Christine Poole; Hedvig Nordeng
Journal:  Eur J Clin Pharmacol       Date:  2016-09-13       Impact factor: 2.953

8.  Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study.

Authors:  K Nezvalová-Henriksen; O Spigset; H Nordeng
Journal:  BJOG       Date:  2013-03-14       Impact factor: 6.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.